Pozen, Inc. (POZN) Submits Final Study Report For PA8140/PA32540 Phase 1 Study On Schedule
4/2/2014 8:32:57 AM
CHAPEL HILL, N.C.--(BUSINESS WIRE)--POZEN Inc. (NASDAQ: POZN), a pharmaceutical company committed to transforming medicine that transforms lives, announced today that they have submitted the final study report for the Phase 1 study comparing the pharmacokinetic profile of the omeprazole component of PA8140 tablets to that of PA32540 tablets as agreed with the U.S. Food and Drug Administration.
Help employers find you! Check out all the jobs and post your resume.
comments powered by